Form 4: Corcept Therapeutics Officer Exercises Options and Sells Shares Under Pre-Planned Trading Plan

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold a portion of his common stock holdings in Corcept Therapeutics Inc. on July 17 and 18, 2025, under a Rule 10b5-1 trading plan.

Summary

• Sean Maduck, President of Corcept Endocrinology, engaged in transactions involving Corcept Therapeutics Inc. common stock on July 17 and 18, 2025.
• On July 17, 2025, Maduck exercised options to acquire 4,315 shares of common stock at an exercise price of $5.05 per share and subsequently sold these 4,315 shares at a weighted average price of $73.4771 per share (ranging from $73.40 to $73.74).
• On July 18, 2025, Maduck exercised options to acquire an additional 473 shares of common stock at an exercise price of $5.05 per share and subsequently sold these 473 shares at a weighted average price of $73.4404 per share (ranging from $73.40 to $73.47).
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Maduck on September 5, 2024.
• Following these transactions, Maduck directly holds 17,705 shares of common stock, which includes 1,877 shares underlying unvested restricted stock awards granted between September 3, 2024, and June 2, 2025.
• Maduck also indirectly holds 89,693 shares through the Sean and Molly Maduck Living Trust and 10,000 shares through Duckhill Capital, LLC.
• As of the filing date, Maduck holds 56,993 unexercised stock options with an exercise price of $5.05, expiring on May 2, 2026.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. While an insider sale can sometimes be viewed negatively, the fact that it was a pre-planned transaction under a 10b5-1 plan, combined with the exercise of options at a significant profit, suggests a routine monetization of equity compensation rather than a lack of confidence in the company's future.

Positives

• The exercise of stock options indicates that the shares were 'in the money,' allowing the officer to realize a significant profit from the difference between the exercise price ($5.05) and the sale price (around $73.40-$73.74).
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests the sales were pre-scheduled and not based on immediate, non-public information, potentially reducing concerns about opportunistic insider selling.

Negatives

• The sale of shares by an officer, even under a 10b5-1 plan, reduces their direct ownership stake in the company.

Future Outlook

NA

Management Comments

• Sean Maduck holds the title of President, Corcept Endocrinology.

Industry Context

This Form 4 filing details routine insider transactions (option exercise and sale) by a senior executive at Corcept Therapeutics, a pharmaceutical company. Such transactions are common in the industry as executives monetize equity compensation, especially when executed under pre-arranged 10b5-1 plans, which are designed to avoid accusations of trading on inside information. This filing does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Sean Maduck indirectly holds 89,693 shares through the Sean and Molly Maduck Living Trust, of which he is a co-trustee.
• Sean Maduck indirectly holds 10,000 shares through Duckhill Capital, LLC, of which he is President, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by an officer could be interpreted in various ways by shareholders, but the 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized from option exercise highlights the value of equity compensation for executives.
• Employees: No direct impact mentioned, but executive compensation structures are relevant to all employees.
• Customers, Suppliers, Creditors: No direct impact.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Sean Maduck, Officer Transaction, Equity Compensation